Summary
Global Markets Direct’s, ‘LEO Pharma A/S - Product Pipeline Review - 2016’, provides an overview of the LEO Pharma A/S’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by LEO Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of LEO Pharma A/S
- The report provides overview of LEO Pharma A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses LEO Pharma A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features LEO Pharma A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate LEO Pharma A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for LEO Pharma A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding LEO Pharma A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
LEO Pharma A/S Snapshot 6
LEO Pharma A/S Overview 6
Key Information 6
Key Facts 6
LEO Pharma A/S - Research and Development Overview 7
Key Therapeutic Areas 7
LEO Pharma A/S - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
LEO Pharma A/S - Pipeline Products Glance 15
LEO Pharma A/S - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
LEO Pharma A/S - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
LEO Pharma A/S - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
LEO Pharma A/S - Drug Profiles 21
(betamethasone dipropionate + calcipotriene) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
LEO-43204 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
aprepitant 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ingenol mebutate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
LEO-124249 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
LP-0113 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LEO-130852A 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
LEO-32731 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LEO-39652 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
VBY-891 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LP-0067 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Antagonize MCHR1 for Weight Loss 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Activate Protein Kinase C for Dermatology and Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LEO Pharma A/S - Pipeline Analysis 35
LEO Pharma A/S - Pipeline Products by Target 35
LEO Pharma A/S - Pipeline Products by Route of Administration 37
LEO Pharma A/S - Pipeline Products by Molecule Type 38
LEO Pharma A/S - Pipeline Products by Mechanism of Action 39
LEO Pharma A/S - Recent Pipeline Updates 40
LEO Pharma A/S - Dormant Projects 43
LEO Pharma A/S - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
(calcipotriene + hydrocortisone butyrate) 44
TD-1414 44
LEO Pharma A/S - Company Statement 45
LEO Pharma A/S - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
LEO Pharma A/S, Key Information 6
LEO Pharma A/S, Key Facts 6
LEO Pharma A/S - Pipeline by Indication, 2016 9
LEO Pharma A/S - Pipeline by Stage of Development, 2016 10
LEO Pharma A/S - Monotherapy Products in Pipeline, 2016 11
LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2016 12
LEO Pharma A/S - Partnered Products in Pipeline, 2016 13
LEO Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2016 14
LEO Pharma A/S - Pre-Registration, 2016 15
LEO Pharma A/S - Phase III, 2016 16
LEO Pharma A/S - Phase II, 2016 17
LEO Pharma A/S - Phase I, 2016 18
LEO Pharma A/S - Preclinical, 2016 19
LEO Pharma A/S - Discovery, 2016 20
LEO Pharma A/S - Pipeline by Target, 2016 36
LEO Pharma A/S - Pipeline by Route of Administration, 2016 37
LEO Pharma A/S - Pipeline by Molecule Type, 2016 38
LEO Pharma A/S - Pipeline Products by Mechanism of Action, 2016 39
LEO Pharma A/S - Recent Pipeline Updates, 2016 40
LEO Pharma A/S - Dormant Developmental Projects,2016 43
LEO Pharma A/S - Discontinued Pipeline Products, 2016 44
LEO Pharma A/S, Subsidiaries 46
List of Figures
LEO Pharma A/S - Pipeline by Top 10 Indication, 2016 8
LEO Pharma A/S - Pipeline by Stage of Development, 2016 10
LEO Pharma A/S - Monotherapy Products in Pipeline, 2016 11
LEO Pharma A/S - Partnered Products in Pipeline, 2016 13
LEO Pharma A/S - Pipeline by Top 10 Target, 2016 35
LEO Pharma A/S - Pipeline by Route of Administration, 2016 37
LEO Pharma A/S - Pipeline by Molecule Type, 2016 38
LEO Pharma A/S - Pipeline Products by Top 10 Mechanism of Action, 2016 39
